Dr Halidou Tinto elected Fellow of the African Academy of Sciences
The PAMAfrica consortium warmly welcomes the election of Dr Halidou Tinto as a Fellow of the prestigious African Academy of Sciences (AAS).
Dr Tinto is the Regional Director of the Institute for Health Sciences Research (IRSS) in Nanoro, Burkina Faso and Head of the Clinical Research Unit of Nanoro (URCN).
The AAS recognizes scientific excellence by electing him into its membership outstanding scholars who have attained the highest distinction in their scientific field and have made significant contributions to the advancement of science regionally and globally.
“We are delighted that Dr Halidou Tinto has been elected as a Fellow of the African Academy of Sciences. Over the years, Novartis has developed a long-standing collaboration with Dr Tinto on several malaria trials, including developing new and innovative treatments for uncomplicated malaria and a new artemether-lumefantrine formulation for small infants. Dr Tinto is one of the most respected scientists and investigators in his field, and Novartis and the entire Malaria team would like to congratulate him warmly on this well-deserved achievement.” (Novartis Malaria Team)
Dr Tinto has 15 years of experience and excellence in clinical trials and has a strong track-record in international scientific collaborations. As the head of the CRUN, and Principal Investigator (PI) or co-principal investigator, he has conducted several phase 2, 3 and 4 clinical trials at ICH/Good Clinical Practice (GCP) standards in collaboration with several academic institutions and pharmaceuticals companies (including Sanofi, Novartis, Sigma Tau, Shin Poong Pharmaceuticals, Janssen). He was also PI on a GSK phase 3 malaria vaccine trial (RTS,S).
In addition to his work at IRSS-CRUN, Dr Tinto is a Professor associated at the Nazi Boni University of Bobo-Dioulasso, Burkina Faso. He is an author/co-author of 181 publications in international peer-reviewed journals.
“The PAMAfrica consortium congratulates Dr Tinto on his admission to the African Academy of Sciences,” said Dr Timothy Wells, Chief Scientific Officer of Medicines for Malaria Venture, one of the leading partners, and Coordinator of the PAMAfrica consortium. “We are delighted to hear of his election to this august body and look forward to working with him on the PAMAfrica clinical trials and benefiting from his expertise.”
IRSS-CRUN, one of the nine partner organizations in the EDCTP-funded PAMAfrica consortium, is working on two clinical trials in the PAMAfrica project, each designed to address a specific unmet medical need. Dr Tinto is a PI on these trials that aim to develop i) a next-generation of drug combinations for uncomplicated malaria and ii) a special formulation of artemether-lumefantrine (AL) for infants < 5 kg in weight.
Here is a link to the article of Dr Tinto’s nomination in French.